Fever Alert: A New Rapid Test to Tell Ebola from Malaria
"This innovative point-of-care diagnostic could revolutionize how we handle outbreaks of deadly hemorrhagic fevers in regions where similar illnesses are common."
Imagine a world where a simple fever could mean any number of dangerous diseases. This is the reality in many parts of the world, particularly in areas where outbreaks of deadly hemorrhagic fevers like Ebola occur alongside common illnesses like malaria. The challenge? Early symptoms are often strikingly similar, making accurate diagnosis based on clinical signs alone incredibly difficult.
The Ebola outbreak in West Africa from 2014 to 2016 underscored the urgent need for better diagnostic tools. Traditional methods like PCR (polymerase chain reaction) are highly accurate but require specialized labs and trained personnel – resources often scarce in outbreak zones. While rapid tests exist, they often lack the ability to differentiate between multiple diseases presenting with similar symptoms.
Now, researchers are offering a promising solution: a new point-of-care diagnostic test that can quickly distinguish between Ebola, Lassa fever, and malaria using a single blood sample. This innovative approach uses surface-enhanced Raman scattering (SERS) to detect antigens from each disease, providing results in under 30 minutes. Let's dive into how this technology works and why it could be a game-changer for outbreak response.
Why Faster Ebola Testing Matters
Ebola virus disease is dangerous and can cause epidemics. Rapid diagnostic tests have been developed to be quicker and easier to use than PCR, the current reference standard. A 2025 laboratory evaluation assessed eight antigen rapid diagnostic tests for detecting Ebola virus (EBOV) and Sudan virus (SUDV), using analytical panels and clinical samples to examine detection limits, sensitivity, and specificity. A 2023 head-to-head comparison reported that QuickNavi-Ebola™ and OraQuick® Ebola Rapid Antigen Test had the most favorable profiles and could support frontline triage while patients await RT-qPCR confirmation.
PCR Remains the Reference
RT-PCR is used as the reference standard in evaluations of Ebola rapid diagnostic tests. The diagnostic accuracy review studied patients presenting to Ebola treatment units with symptoms of Ebola virus disease and compared rapid tests with RT-PCR. WHO's July 2026 guidance addresses diagnostic testing for Ebola and Marburg virus diseases for laboratory personnel, clinicians, health workers, public health officials, and outbreak-response teams. A separate 2026 discussion describes RT-PCR as a molecular diagnostic approach whose reliability depends on appropriate specimen collection and transport materials.
How Does the SERS Diagnostic Work?
The SERS-based diagnostic hinges on a clever use of nanotechnology. Here's a breakdown of the key components:
- Silica Shell: The gold nanoparticle and Raman reporter are encased in a silica shell. This shell acts as a protective barrier, preventing the reporter from detaching and blocking unwanted signals from the blood sample.
- Antibodies: The silica shell is coated with antibodies that are specific to antigens (proteins) from Ebola, Lassa fever, or malaria. These antibodies act like tiny hooks, grabbing onto the target antigens if they're present in the sample.
- Magnetic Microparticles: These particles are also coated with the same antibodies, creating a "sandwich" effect. When the target antigen is present, it binds to both the SERS nanotag and the magnetic microparticle.
One Sample, Multiple Targets
A review of plasmonics describes a SERS-tag immunoassay designed to detect Ebola, Lassa, and malaria antigens simultaneously in a single blood sample. The cited Ebola and malaria work used SERS nanotagging technology with whole blood and serum. Its reported study groups included 100 Ebola-positive and 486 Ebola-negative samples, alongside 163 malaria-positive and 233 malaria-negative samples. The approach is also identified in Sebba and colleagues' 2018 Science Translational Medicine paper, titled 'A point-of-care diagnostic for differentiating Ebola from endemic febrile diseases.'
Accuracy Requires Scrutiny
A January 2025 systematic review and meta-analysis examined studies and reports comparing antigen rapid diagnostic tests for Ebola disease. The researchers searched PubMed, EMBASE, and Web of Science for diagnostic studies published between 1976 and 2023. They evaluated the studies with the QUADAS-2 tool. A separate 2026 guide emphasizes that Ebola diagnosis involves clinical recognition, sample collection, RT-PCR testing, and point-of-care rapid tests, while noting the importance and field challenges of early diagnosis.
Rapid Tests Versus RT-PCR
A 2022 systematic review and meta-analysis describes lateral-flow rapid diagnostic tests as suitable for broad deployment. It reports that these tests are typically well-suited to rapidly diagnosing hemorrhagic-fever viruses such as Ebola virus. Their practical value in this comparison is speed and deployability rather than replacement of every role served by RT-PCR. The source specifically frames rapid tests in relation to RT-PCR for Ebola virus infections.
Why This Matters
This new SERS-based diagnostic offers several key advantages:
Lessons From Major Outbreaks
The 2014/15 Ebola outbreak in West Africa resulted in 11,000 deaths and placed massive strain on local health systems. The ongoing outbreak in the Democratic Republic of Congo had affected more than 3,000 people when the cited study was reported. These events underscore the need for accurate, rapid Ebola diagnostics that are suitable for outbreak settings. The study focuses on comparing the performance of three Ebola rapid diagnostic tests.
Speed Can Protect Patients and Staff
Point-of-care rapid diagnostic tests could substantially reduce delays in Ebola diagnosis. Earlier testing may allow patients to be triaged sooner and reduce potential nosocomial transmission. In the Democratic Republic of the Congo, which had experienced 13 Ebola virus disease outbreaks since 1976, antigen-detecting rapid tests were developed to address difficulties with RT-PCR in remote, low-resource settings. However, the field-performance study noted continuing uncertainty about these tests' performance characteristics and usability during outbreaks.
Speed and Simplicity: Results are available in under 30 minutes, and the test requires minimal training and equipment.
Multiplexing: The ability to test for multiple diseases simultaneously is crucial in areas where overlapping infections are common. Cost-Effectiveness: The potential for low-cost production makes this test accessible to resource-limited settings. Temperature Stability: The reagents are designed to be stable at ambient temperatures, eliminating the need for refrigeration. While further research is needed, including real-world testing during outbreaks, this SERS technology holds tremendous promise for improving our ability to diagnose and respond to deadly infectious diseases. It’s a significant step toward a future where a simple fever doesn’t have to be a terrifying mystery.